Next Article in Journal
In Vitro and In Vivo Antioxidant Activity of a Water-Soluble Polysaccharide from Dendrobium denneanum
Next Article in Special Issue
DNA Libraries for the Construction of Phage Libraries: Statistical and Structural Requirements and Synthetic Methods
Previous Article in Journal
Identification and Characterization of Three Novel Small Interference RNAs That Effectively Down-Regulate the Isolated Nucleocapsid Gene Expression of SARS Coronavirus
Previous Article in Special Issue
Material Binding Peptides for Nanotechnology
Article Menu

Export Article

Open AccessArticle
Molecules 2011, 16(2), 1559-1578;

Challenges in Optimizing a Prostate Carcinoma Binding Peptide, Identified through the Phage Display Technology

Department of Radiooncology and Radiation Therapy, University of Heidelberg, INF 400, 69120, Heidelberg, Germany
Research Laboratories, Bayer Schering Pharma AG, Berlin, Germany
Clinical Cooperation Unit Nuclear Medicine, German Cancer Research Center, INF 260, 69120, Heidelberg, Germany
Department of Nuclear Medicine, University of Heidelberg, INF 400, 69120 Heidelberg, Germany
Author to whom correspondence should be addressed.
Received: 15 December 2010 / Revised: 9 February 2011 / Accepted: 11 February 2011 / Published: 14 February 2011
(This article belongs to the Special Issue Phage Display of Combinatorial Libraries)
PDF [475 KB, uploaded 18 June 2014]


The transfer of peptides identified through the phage display technology to clinical applications is difficult. Major drawbacks are the metabolic degradation and label instability. The aim of our work is the optimization of DUP-1, a peptide which was identified by phage display to specifically target human prostate carcinoma. To investigate the influence of chelate conjugation, DOTA was coupled to DUP-1 and labeling was performed with 111In. To improve serum stability cyclization of DUP-1 and targeted D-amino acid substitution were carried out. Alanine scanning was performed for identification of the binding site and based on the results peptide fragments were chemically synthesized. The properties of modified ligands were investigated in in vitro binding and competition assays. In vivo biodistribution studies were carried out in mice, carrying human prostate tumors subcutaneously. DOTA conjugation resulted in different cellular binding kinetics, rapid in vivo renal clearance and increased tumor-to-organ ratios. Cyclization and D-amino acid substitution increased the metabolic stability but led to binding affinity decrease. Fragment investigation indicated that the sequence NRAQDY might be significant for target-binding. Our results demonstrate challenges in optimizing peptides, identified through phage display libraries, and show that careful investigation of modified derivatives is necessary in order to improve their characteristics. View Full-Text
Keywords: phage display; peptide; prostate carcinoma; radiolabeling; affinity phage display; peptide; prostate carcinoma; radiolabeling; affinity

Figure 1

This is an open access article distributed under the Creative Commons Attribution License (CC BY 3.0).

Share & Cite This Article

MDPI and ACS Style

Askoxylakis, V.; Zitzmann-Kolbe, S.; Zoller, F.; Altmann, A.; Markert, A.; Rana, S.; Marr, A.; Mier, W.; Debus, J.; Haberkorn, U. Challenges in Optimizing a Prostate Carcinoma Binding Peptide, Identified through the Phage Display Technology. Molecules 2011, 16, 1559-1578.

Show more citation formats Show less citations formats

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Molecules EISSN 1420-3049 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top